Pfizer new 'final' offer rejected by AstraZeneca

UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer.

Pfizer had made a new offer of £55 per share, valuing AstraZeneca at about £69bn.

But AstraZeneca says the new proposal "undervalues the company and its attractive prospects".

Kamal Ahmed reports.